CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number: NDA 20375/S005

APPROVAL LETTER

NDA 20-375/S-005

Berlex Laboratories, Inc. Attention: Ms. Jo-Ann M. Ruane Manager 300 Fairfield Road WAYNE NJ 07470

Dear Ms. Ruane:

Please refer to your January 31, 1996, supplemental new drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Climara (estradiol transdermal system).

This supplemental application provides for a packaging site change for an approved secondary packager of the drug product.

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Ms. Christina Kish at 310-443-3520.

Sincerely yours,

/\$/ 5/17/16

Helen W. Davies, Ph.D.
Chemistry Team Leader I, DNDC II
Division of Metabolism and
Endocrine Drug Products (HFD-510)
Office of New Drug Evaulation II
Center for Drug Evaluation and Research

cc:
Orig. NDA
HFD-510
DISTRICT OFFICE
HFD-80
HFD-510/HDavies
HFD-510/CKish/5.2.96/n20375ap.s5
concurrences:HDavies 5.7.96/EGalliers 5.16.96
SUPPLIMENT APPROVAL (S/AP)